SCM
SPRY icon

Sio Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Sio Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-217,864
Closed -$1.85M – 53
2024
Q2 		$1.85M Sell
217,864
-318,299
-59% -$2.82M 0.5% 31
2024
Q1 		$5.48M Sell
536,163
-569,748
-52% -$4.25M 1.63% 19
2023
Q4 		$6.06M Hold
1,105,911
– – 1.38% 17
2023
Q3 		$4.18M Buy
1,105,911
+563,335
+104% +$3.7M 1.29% 22
2023
Q2 		$3.64M Buy
+542,576
New +$3.62M 0.92% 22

Other funds holding SPRY

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Sio Capital Management's SPRY Position: Q3 2024 in Review

Sio Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2024, closing a stake of 217,864 shares — an estimated $1.85M sold.

Sio Capital Management first reported a position in SPRY in Q2 2023 and held it in 5 quarters. The position peaked at $6.06M in Q4 2023. 151 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • Sio Capital Management reported no remaining ARS Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Sio Capital Management sold 217,864 ARS Pharmaceuticals shares in Q3 2024, an estimated $1.85M.
  • Sio Capital Management first reported a position in ARS Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Sio Capital Management's ARS Pharmaceuticals position peaked at $6.06M in Q4 2023.
  • 151 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on Sio Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.